FindTrial
Sign In

Observational study of efficacy and adverse effects of immune checkpoint inhibitors

Observational study of efficacy and adverse effects of immune checkpoint inhibitors - Observational study of efficacy and adverse effects of immune checkpoint inhibitors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066188
Enrollment
Unknown
Registered
2022-11-27
Start date
2022-11-30
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series:None

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who need to receive IPIs for lung cancer; 2. Age >= 18 years old; 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Mental disorders or cognitive dysfunction; 2. Factors that other researchers believe affect the experiment.

Design outcomes

Primary

MeasureTime frame
immune-related adverse events;—

Countries

China

Contacts

Public ContactZhou Jian

Peking University People's Hospital

zhoujian@bjmu.edu.cn+86 88326650

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026